Cleto, Cheery Mae R.

HRN: 00-35-23  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/19/2022
CO-AMOXICLAV 625MG (TAB)
10/19/2022
10/26/2022
ORAL
625mg
Q12
T/C Endometritis
Waiting Final Action 

Indication:  ProphylaxisEmpiric    Type of Infection:  Reproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: No  Wrong Choice  Wrong Choice

Overall appropriateness: No  Wrong Choice

Intervention



Type of Intervention done:

                    

           


Acceptance: